SamirDineshUndeviaMD
Hematology • Chicago, ILMyeloproliferative Disorder Hematology-Oncology
Clinical Associate of Medicine, University of Chicago Medicine
Are you Dr. Undevia?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 114 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
901 W Wellington Ave
Chicago, IL 60657Phone+1 773-296-5397Fax+1 773-296-7731
Summary
- Dr. Samir Undevia, MD is a hematologist in Chicago, Illinois. He is currently licensed to practice medicine in Illinois. He is affiliated with University of Chicago Medical Center, Loyola University Medical Center, and Edward Hospital.
Education & Training
University of ChicagoFellowship, Hematology and Medical Oncology, 2001 - 2004- University of ChicagoResidency, Internal Medicine, 1997 - 2000
New York University School of MedicineClass of 1997
Certifications & Licensure
IL State Medical License 2000 - 2026- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- West Suburban Living Magazine Castle Connolly, 2014
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
- Super Doctor SuperDoctors.com
Clinical Trials
- Cilengitide (EMD 121974) in Treating Patients With Advanced Solid Tumors or Lymphoma Start of enrollment: 2003 Dec 01
- Study of the Tolerability, Safety, and Pharmacokinetics of CRA-024781 in Cancer Patients Start of enrollment: 2005 Aug 01
- Study of the Safety and Tolerability of Oral Capsule Form of PCI-24781 in Advanced Cancer Patients Start of enrollment: 2007 Nov 01
- Join now to see all
Publications & Presentations
PubMed
- 47 citationsResults of a prospective phase 2 study of pazopanib in patients with surgically unresectable or metastatic chondrosarcomaWarren Chow, Paul Frankel, Chris Ruel, Dejka M. Araujo, Mohammed M. Milhem
Cancer. 2020-01-01 - 22 citationsPhase II randomised discontinuation trial of brivanib in patients with advanced solid tumoursRobin L. Jones, Mark J. Ratain, Peter J. O'Dwyer, Lillian L. Siu, Jacek Jassem
European Journal of Cancer. 2019-10-01 - Correction to: Doxorubicin plus the IGF-1R antibody cixutumumab in soft tissue sarcoma: a phase I study using the TITE-CRM modelRashmi Chugh, Kent A. Griffith, Elizabeth J. Davis, Dafydd G. Thomas, J. D. Zavala
Annals of Oncology. 2019-08-01
Professional Memberships
- Member
